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Abstract
Background: Despite the large number of men diagnosed with localized prostate cancer, there is as yet no consensus 
concerning appropriate treatment. The purpose of this study was to describe the initial treatment patterns for localized 
prostate cancer in a population-based sample and to determine the clinical and patient characteristics associated with 
initial treatment and overall survival.
Methods: The analysis included 3,300 patients from seven states, diagnosed with clinically localized prostate cancer in 
1997. We examined the association of sociodemographic and clinical characteristics with four treatment options: 
radical prostatectomy, radiation therapy, hormone therapy, and watchful waiting. Diagnostic and treatment 
information was abstracted from medical records. Socioeconomic measures were derived from the 2000 Census based 
on the patient's residence at time of diagnosis. Vital status through December 31, 2002, was obtained from medical 
records and linkages to state vital statistics files and the National Death Index. Multiple logistic regression analysis and 
Cox proportional hazards models identified factors associated with initial treatment and overall survival, respectively.
Results: Patients with clinically localized prostate cancer received the following treatments: radical prostatectomy 
(39.7%), radiation therapy (31.4%), hormone therapy (10.3%), or watchful waiting (18.6%). After multivariable 
adjustment, the following variables were associated with conservative treatment (hormone therapy or watchful 
waiting): older age, black race, being unmarried, having public insurance, having non-screen detected cancer, having 
normal digital rectal exam results, PSA values above 20, low Gleason score (2-4), comorbidity, and state of residence. 
Among patients receiving definitive treatment (radical prostatectomy or radiation therapy), older age, being 
unmarried, PSA values above 10, unknown Gleason score, state of residence, as well as black race in patients under 60 
years of age, were associated with receipt of radiation therapy. Overall survival was related to younger age, being 
married, Gleason score under 8, radical prostatectomy, and state of residence. Comorbidity was only associated with 
risk of death within the first three years of diagnosis.
Conclusions: In the absence of clear-cut evidence favoring one treatment modality over another, it is important to 
understand the factors that inform treatment selection. Since state of residence was a significant predictor of both 
treatment as well as overall survival, true regional differences probably exist in how physicians and patients select 
treatment options. Factors affecting treatment choice and treatment effectiveness need to be further explored in 
future population-based studies.
Background
Despite the large number of men diagnosed with local-
ized prostate cancer, there is as yet no consensus con-
cerning appropriate treatment. In response to two
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Page 2 of 15Institute of Medicine reports suggesting that central can-
cer registries be utilized for tracking cancer treatment
[1,2] the Centers for Disease Control and Prevention's
(CDC) National Program of Cancer Registries (NPCR)
undertook a multi-state Patterns of Care study to identify
cancer treatment in a cross-section of the United States.
In order to include follow-up data for survival analysis in
the project, the study design was retrospective, based on
cancers diagnosed in 1997.
According to the National Cancer Institute's (NCI's)
Physician Data Query from 1996, acceptable treatment
options for localized prostate cancer included surgical
removal of all of the prostate and some surrounding tis-
sue (radical prostatectomy); radiation therapy, either
external beam or interstitial (brachytherapy); and careful
observation without further immediate treatment
("watchful waiting"). Hormone therapy, another option,
could be achieved by either orchiectomy (surgical
removal of the testicles) or the administration of drugs to
block hormone production or action [3]. These recom-
mendations have not changed substantially in the inter-
vening years [4]. According to the current Clinical
Practice Guidelines of the National Comprehensive Can-
cer Network [5], observation, radiation, and radical pros-
tatectomy are all reasonable treatment options for
localized prostate cancer, the treatment decision being
based on balancing expected long-term survival in the
absence of treatment against individual tolerance for the
side effects of current therapies.
Objectives
The objectives of the current study were to describe the
initial treatment patterns for localized prostate cancer in
a population-based sample and to determine the clinical
and patient characteristics associated with initial treat-
ment. In particular, what factors are related to choice of
conservative management versus definitive treatment;
and among patients receiving definitive treatment, what
factors are related to radiation therapy versus radical
prostatectomy? Radical prostatectomy and radiation
therapy are viewed as definitive treatment for localized
prostate cancer; that is, they are potentially curative
because they remove or destroy cancerous tissue. Hor-
mone therapy and watchful waiting are considered non-
curative and are classified as conservative management.
A secondary objective of the current study was to deter-
mine whether mode of initial treatment for localized
prostate cancer was related to patient survival.
Methods
The CDC-NPCR Breast, Colon, and Prostate Cancer
Data Quality and Patterns of Care Study (PoC1) involved
seven participating states (California, Colorado, Illinois,
Louisiana, New York, Rhode Island, and South Carolina)
and the CDC. The sampling methodology for this study
has been explained in detail elsewhere [6,7]. In brief, ran-
dom samples of cancer patients diagnosed in 1997 were
selected from the databases of the participating central
cancer registries. Institutional Review Board approval for
use of the data was obtained at every participating uni-
versity or health department and at the Centers for Dis-
ease Control and Prevention.
Inclusion Criteria
Patients included in the current analysis were those diag-
nosed in 1997 with a first primary prostate cancer (ICD-
O-2: C61.9; Behavior = 3; sequence number 00 or 01),
diagnosed at a clinically localized stage. Since the deter-
mination of pathologic staging requires histologic exami-
nation of the resected specimen, usually involving total
prostatoseminalvesiculectomy and pelvic lymph node
dissection [8], pathologic staging would only be available
for patients who had undergone radical prostatectomy.
Patients were considered to have clinically localized dis-
ease if (1) the tumor was clinically inapparent (i.e., not
palpable or visible by imaging) or (2) the tumor was con-
fined within the prostate (cT1c and cT2), and there was
no clinical evidence of nodal involvement and no evi-
dence of metastasis. Frequently, when pathologic staging
information was available in the medical record, clinical
staging information was not documented. Therefore,
patients with pathologic assessment of the tumor (pT1
and pT2) were also included as long as there was no clini-
cal evidence of nodal involvement and no evidence of
metastasis. Additionally, only patients with microscopi-
cally confirmed adenocarcinomas who were alive six
months post diagnosis were included in the analysis.
Measurement
Hospital medical records of the study cases were reab-
stracted by specially trained staff in each state, using a
common data entry form. Demographic, diagnostic, stag-
ing, and treatment data were obtained for each patient
from hospital charts, supplemented by records from phy-
sicians' offices and from ambulatory surgery and radia-
tion therapy facilities. Because the proportion of
Hispanics residing in many parts of the study area was
low, Hispanic ethnicity was frequently not noted in the
medical record (e.g., the hospital intake form did not
include an ethnicity check-off ). Patients were categorized
as non-Hispanic unless there was evidence to the con-
trary (e.g., reference to Hispanic ethnicity in the history
and physical section of the medical record). Race and eth-
nicity information was combined to create four groups:
Hispanic, non-Hispanic White, non-Hispanic Black, and
non-Hispanic other (including Asian/Pacific Islander).
ICD-9-CM codes that were recorded in medical records
were abstracted to assess the presence of comorbid ill-
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son index were consolidated into a summary Charlson
measure [9]. Insurance status was also determined from
medical records. Private insurance included those with
either private insurance or Medicare with a supplement.
Public insurance included those with Medicare, Medicaid
or welfare, or other federally funded health insurance. For
a small proportion of patients, insurance type was indi-
cated as "other".
Each patient's address was geocoded at the participat-
ing registry to the census tract level. The records were
subsequently linked by census tract to the following
socio-demographic indicators, derived from the 2000
census data: poverty (<20% versus 20%+ of residents
below the 2000 poverty level); education (<25% versus
25%+ of residents age twenty-five and over with less than
a high school education); working class status (<66% ver-
sus 66%+ working class occupations); and urban-rural
residence (totally urban, totally rural, urban-rural mix, or
unknown). Indicators were selected based on the work of
Nancy Krieger [10]. Vital status as of December 31, 2002,
was obtained from medical records, physician offices,
and by linking to state vital statistics files and to the
National Death Index (NDI) for 1997 through 2002. At
the time funding for the study ended, 2002 was the last
year for which data from NDI were available.
Initial treatment was defined as treatment received
within the first six months following diagnosis. A hierar-
chical variable was created to categorize treatment, rang-
ing from the most aggressive to the least aggressive [11].
Men who received radical prostatectomy were assigned
to radical prostatectomy, whether or not they received
any other therapy. Men who received radiation therapy
(external beam or interstitial) were assigned to radiation
therapy, whether or not they also received hormone ther-
apy. The hormone therapy category was comprised of
men who only received hormone therapy (medical or sur-
gical). Men who had no record of any therapy within the
first six months following diagnosis were assigned to the
watchful waiting category. Whether or not cases with
missing treatment data were excluded from analysis
depended on what treatment data were missing relative
to the treatment hierarchy. For example, patients with
missing surgery information were excluded. However,
patients with missing hormone information were still eli-
gible for inclusion in the radical prostatectomy or radia-
tion therapy categories. Patients who died within six
months of diagnosis were deleted from all analyses
because determination of treatment mode was based on
the six month post-diagnosis timeframe.
Data Analyses
We examined the proportion of patients receiving each
type of therapy by sociodemographic and clinical factors.
Bivariate analysis was used to examine the association
between the four major treatment options and patient
and tumor characteristics. The analytic variables
included age at diagnosis, race/ethnicity, marital status,
insurance, education, poverty, working class status,
urban-rural residence, registry, whether the tumor was
screen detected, digital rectal exam (DRE) results, PSA
value, Gleason score, and Charlson comorbidity score.
Two-sided chi-square tests were used to compare the dis-
tribution of treatments across the predictor variables.
Variables found to be significantly associated in the bivar-
iate analysis were included in the multivariable logistic
regression models. For the multivariable analyses, marital
status was dichotomized into married and not married
(single, separated, divorced, and widowed). "Other"
insurance was combined with private insurance. Separate
logistic regression analyses were conducted to identify
factors associated with receipt of conservative manage-
ment and factors associated with receipt of radiation
therapy among those receiving definitive treatment. A
backward selection approach was utilized. That is, non-
significant and non-relevant variables were deleted from
the model one at a time. At each step, the change in
parameter estimates for the remaining variables was
examined to determine whether non-significant variables
should be retained to control for confounding. The Hos-
mer-Lemeshow test was used to assess the goodness of fit
of the model.
We examined all cause survival from diagnosis through
December 31, 2002, conditional upon having survived six
months following diagnosis (i.e., patients had to have sur-
vived six months to be included in this study). The pro-
portion of patients surviving five years following
diagnosis was estimated using the life table method. Cox
proportional hazards models were used to estimate crude
and adjusted hazard ratios. A backward selection
approach was utilized to determine which factors to
include in the final model. Time-varying covariates were
used to test the proportional hazards assumption, which
was violated for comorbidity. Therefore, time-varying
covariates for comorbidity were retained in the final
model. SAS statistical software (version 9.1, SAS Insti-
tute, Cary, NC) was used for all analyses.
Results
A total of 3,504 patients with localized primary prostate
cancer were identified. Of these, 176 were excluded from
analysis for the following reasons: diagnosis year was not
1997 (n = 3), tumor was not microscopically confirmed (n
= 23), histology other than adenocarcinoma (n = 3),
month of diagnosis was unknown (n = 51), information
on treatment or treatment dates was missing (n = 64), or
died within six months of diagnosis (n = 53). Some
patients were excluded for multiple reasons. A total of
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the analysis of conservative versus definitive treatment.
Twenty-eight of these patients did not have a radical
prostatectomy or receive radiation therapy but were
missing information on hormone therapy. Consequently,
they could be included in conservative management but
not in the specific treatment groupings shown in Table 1.
Except for urban-rural residence, all other variables
considered in the bivariate analysis were found to be sta-
tistically significantly associated with mode of initial
treatment (Tables 1 and 2). The proportion of prostate
cancers treated surgically decreased dramatically with
age. As the proportion of radical prostatectomy
decreased, the proportion of radiation therapy increased
until age 75-79. Thereafter, conservative treatment pre-
dominated. Radical prostatectomy was the predominant
mode of initial treatment for all race/ethnic groups
except non-Hispanic other. Non-Hispanic white men
were least likely to receive conservative management.
The proportions of both types of definitive treatment
were highest among married men. The overwhelming
majority of men in our sample had private insurance.
Men with public insurance were least likely to receive
surgical treatment and most likely to receive conservative
management. Patients residing in high education census
tracts were more apt to have been surgically treated, as
were patients residing in non-poverty census tracts and
patients in non-working class census tracts. Treatment
patterns varied geographically. The proportion of men
with clinically localized prostate cancer who underwent
radical prostatectomy was highest in Colorado (44.2%)
and lowest in New York (34.9%). Receipt of radiation
therapy was highest in New York (40.7%) and lowest in
California (25.3%). Less absolute variability was observed
in the proportion of men who underwent conservative
management (range: 26.1% in New York to 32.4% in Illi-
nois). The predominant mode of radiotherapy was exter-
nal beam. Of the 1,037 patients treated with radiation,
74.8% received external beam radiation, 16.7% received
brachytherapy, virtually all of which was permanent
implant, and 8.5% received both (data not shown).
The distribution of initial treatment by clinical and
tumor characteristics is shown in Table 2. In general, less
aggressive tumors, that is, tumors that were screen
detected or were not palpable by DRE or had low PSA
values or low Gleason scores, were more likely to be
treated surgically than with radiation therapy. Both types
of definitive treatment decreased as the comorbidity
score increased.
Crude and adjusted odds ratios for receipt of conserva-
tive management are shown in Table 3. No statistically
significant differences in receipt of conservative manage-
ment were observed for census-based socioeconomic
indicators after adjustment for other variables. As
expected, the likelihood of receiving conservative man-
agement increased dramatically with age. The odds of
receiving conservative management among patients 60-
64 years of age were 65% greater than among men below
age 60. The corresponding odds for patients in their 80 s
were 27 times greater than for patients below age 60.
Black non-Hispanics were more likely to receive conser-
vative therapy than White non-Hispanics. Unmarried
patients were more likely to receive conservative therapy
than those that were married. Patients with public insur-
ance were more likely to receive conservative treatment
than patients with private insurance. Men with localized
prostate cancer residing in Louisiana and South Carolina
were less likely to receive conservative management than
men residing in California. Differences in the likelihood
of conservative management did not differ significantly
between California and the states of Illinois, New York,
and Rhode Island, whereas the likelihood was marginally
higher in Colorado. Men with screen-detected prostate
cancer were less likely to receive conservative therapy
than men whose cancer was not screen-detected. Patients
whose DRE results were abnormal were less likely to
receive conservative therapy than patients with normal
DRE results. PSA value was associated with receipt of
conservative treatment but only at very high values, that
is, at values above 20. Patients whose tumors were mod-
erately or poorly differentiated (Gleason score 5-10) were
less likely to receive conservative treatment than patients
with well differentiated tumors (Gleason score 2-4). The
likelihood of receiving conservative treatment increased
with the number of comorbidities.
Crude and adjusted odds ratios for receipt of radiation
therapy among patients receiving definitive treatment are
shown in Table 4. After adjustment for the other variables
in the model, no statistically significant differences were
observed for census- based socioeconomic indicators,
type of insurance, whether the cancer was screen
detected, or comorbidity score. Race/ethnicity also
appeared to be a non-significant factor. However, two
alternative models fit the data equally well. The first
model contains an age-race/ethnicity interaction. The
second model does not contain race/ethnicity. The odds
ratios for all other factors vary negligibly between the two
models.
Within the interaction term, race was dichotomized
into non-Hispanic Black and all others. Within both race/
ethnicity categories, the likelihood of receiving radiation
therapy as opposed to radical prostatectomy increased
with age although much less steeply for non-Hispanic
Blacks (Table 5). However, the odds of receiving radiation
therapy for non-Hispanic Blacks under age 60 were 2.6
times greater than the odds for other men of the same
age. At ages 60 and greater, the odds of receiving radia-
tion therapy did not vary by race/ethnicity.
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Page 5 of 15Table 1: Distribution of initial treatment by sociodemographic and economic characteristics of the patient.
Percent receiving each therapy









Total 3,328 (100) 3,300 (100) 39.70 31.42 10.27 18.61
Age at diagnosis
<60 602 (18) 601 (18) 72.88 15.14 3.00 8.99 <0.0001
60-64 568 (17) 565 (17) 61.42 21.06 5.13 12.39
65-69 736 (22) 730 (22) 48.36 31.92 7.26 12.47
70-74 709 (21) 703 (21) 20.91 47.08 10.81 21.19
75-79 456 (14) 453 (14) 4.42 49.23 17.88 28.48
>= 80 257 (8) 248 (8) 2.02 16.13 33.06 48.79
Race/ethnicity
Non-Hispanic White 2,671 (80) 2,649 (80) 40.43 32.58 9.82 17.18 0.0011
Non-Hispanic Black 465 (14) 460 (14) 36.74 26.09 13.26 23.91
Non-Hispanic Other 56 (2) 56 (2) 32.14 33.93 8.93 25.00
Hispanic 114 (3) 113 (3) 41.59 23.01 8.85 26.55
Unknown 22 (1) 22 (1) 22.73 40.91 13.64 22.73
Marital status
Married 2,508 (75) 2,489 (75) 43.51 31.90 9.04 15.55 <0.0001
Single 232 (7) 229 (7) 34.06 27.07 10.04 28.82
Separated/divorced 174 (5) 173 (5) 39.88 26.01 10.40 23.70
Widowed 234 (7) 230 (7) 16.96 31.74 19.13 32.17
Unknown 180 (5) 179 (5) 22.91 35.20 16.20 25.70
Insurance
None 26 (1) 26 (1) 42.31 26.92 11.54 19.23 <0.0001
Private 2,384 (72) 2,365 (72) 42.79 31.63 9.56 16.03
Public 570 (17) 564 (17) 31.56 28.90 13.12 26.42
Other 94 (3) 94 (3) 53.19 24.47 7.45 14.89
Unknown 254 (8) 251 (8) 23.51 38.25 11.55 26.69
Education4
Educated 2,431 (73) 2,409 (73) 41.22 31.51 9.46 17.81 0.0062
Not educated 880 (26) 874 (26) 35.81 30.78 12.59 20.82
Poverty4
Not in poverty 2,546 (77) 2,529 (77) 40.45 31.99 9.65 17.91 0.0275
In poverty 765 (23) 754 (23) 37.53 29.05 12.47 20.95
Working class status4
Non-working class 1,738 (52) 1,724 (52) 40.14 33.29 9.40 17.17 0.0165
Working class 1,573 (47) 1,559 (47) 39.38 29.12 11.29 20.21
Urban-rural residence4
100% urban 2,196 (66) 2,174 (66) 39.93 31.05 9.84 19.18 0.4804
Urban-rural mix 853 (26) 848 (26) 40.57 31.13 10.85 17.45
100% rural 262 (8) 261 (8) 36.02 34.10 12.26 17.62
Schymura et al. BMC Cancer 2010, 10:152
http://www.biomedcentral.com/1471-2407/10/152
Page 6 of 15Among men who received definitive treatment, unmar-
ried patients were more likely to receive radiation therapy
than married patients. With the exception of Louisiana,
patients residing in the remaining five states were signifi-
cantly more likely to receive radiation therapy than
patients residing in California. Prostate cancer patients
with PSA values above 10 were more likely to receive
radiation therapy. Men with poorly differentiated tumors
(Gleason score 8-10) were more likely to receive radiation
therapy than men with well differentiated tumors (Glea-
son score 2-4).
The survival analysis was limited to 3,297 patients.
Three patients for whom information on year of last con-
tact was missing were excluded from the 3,300 patients
with known treatment modality (n = 3,300; see Table 1).
All sociodemographic, economic, and clinical character-
istics shown in Tables 1 and 2 were found to be signifi-
cantly associated with survival, as was treatment
modality. Five-year survival rates and crude and adjusted
hazard ratios for factors retained in the final model are
shown in Table 6. The proportional hazards assumption
for comorbidity was found to hold for the following inter-
vals: ≤ 1 year post-diagnosis; >1 to 3 years post-diagnosis;
and >3 years post-diagnosis.
Risk of death from any cause increased substantially
with age. Hispanic men had a significantly lower risk of
death than non-Hispanic white men; this difference
remained borderline significant after adjusting for other
factors (p = 0.0511). Married men had a lower risk of
death than unmarried men; this difference also remained
borderline significant after adjustment (p = 0.0551). Five-
year survival rates varied by state of residence, from
78.8% for Louisiana to 90.0% for Colorado. After adjust-
ing for other factors, the hazard ratio remained signifi-
cantly higher (significantly lower survival) for Louisiana
and South Carolina. Risk of death increased with increas-
ing PSA levels. However, the increase in risk attenuated
after adjustment for other factors; only men with
unknown PSA levels remained at significantly increased
risk. Men with undifferentiated tumors, Gleason score 8-
10, or with tumors of unknown grade were at significantly
higher risk of death even after adjusting for other factors.
Five-year survival varied significantly with treatment
modality; survival was highest for patients who received
radical prostatectomy (93.7%) and lowest for patients
who received hormone therapy (65.2%). For patients who
received radiation therapy and for patients who under-
went watchful waiting, the five-year survival rates were
86.0% and 74.5%, respectively. Even after adjusting for
factors that were predictive of treatment, patients who
did not receive a radical prostatectomy were significantly
more likely to die. The risk of death associated with
comorbid conditions attenuated with time since diagno-
sis; the attenuation was greater after adjusting for other
factors. Within the first year following diagnosis, the haz-
ard ratio was 2.16 for patients with a comorbidity score of
1 and 6.39 for patients with a score of 2 or more. One to
three years post diagnosis, patients with a comorbidity
score of 1 were no longer at increased risk of dying com-
pared to patients with no comorbidity, whereas patients
with a comorbidity score of 2 or more were still at signifi-
cantly increased risk but the hazard ratio was reduced to
2.67. Three years after diagnosis, comorbidity at diagno-
sis was no longer associated with survival. After adjust-
ment for other factors, no statistically significant
differences in survival were observed for insurance, edu-
cation, poverty, working class status, urban-rural resi-
dence, whether the tumor was screen detected, or digital
rectal exam (DRE) results.
We found further survival differences within the group
receiving radiation therapy. Compared to radical pros-
tatectomy, the adjusted hazard ratio and 95% confidence
intervals for brachytherapy, external beam radiation, and
combined radiotherapy were 0.58 (0.29, 1.16), 1.90 (1.41,
2.55), and 1.70 (0.93, 3.08), respectively. Thus the appar-
ent survival advantage of radical prostatectomy com-
Registry
California 507 (15) 503 (15) 43.74 25.25 12.52 18.49 <0.0001
Colorado 509 (15) 507 (15) 44.18 28.60 10.45 16.77
Illinois 522 (16) 521 (16) 36.28 31.48 10.36 21.88
Louisiana 530 (16) 529 (16) 42.53 26.47 11.53 19.47
New York 445 (13) 435 (13) 34.94 40.69 9.43 14.94
Rhode Island 464 (14) 459 (14) 36.17 35.29 8.71 19.83
South Carolina 351 (11) 346 (10) 38.73 35.26 7.80 18.21
1: Sample size for analysis of conservative versus definite therapy.
2: Sample size for dividing conservative treatment into hormone therapy and watchful waiting (excludes 28 observations missing dates for 
hormone therapy). Used for calculating proportions in this table.
3: Probability from a two-sided X2 test comparing the distribution of treatments across levels of the variable.
4: Information missing for 17 individuals.
Table 1: Distribution of initial treatment by sociodemographic and economic characteristics of the patient. (Continued)
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radiation. The adjusted hazard ratios for the covariates
shown in Table 6 did not change appreciably with the
introduction of the additional treatment terms into the
model (data not shown).
Discussion
The rates of radical prostatectomy and radiation therapy
observed in our study are comparable to those observed
for patients in areas covered by the National Cancer Insti-
tute's (NCI) Surveillance, Epidemiology and End Results
(SEER) program diagnosed in 1997 with a first primary,
localized prostate cancer; that is 35.5% and 30.5% for rad-
ical prostatectomy and radiation therapy, respectively
[12]. However, these rates differ from what was observed
in the NCI Prostate Cancer Outcomes Study [11], which
showed higher rates of radical prostatectomy and lower
rates of radiation therapy. Part of the difference may
reflect temporal trends, since the NCI study was based on
1994 and 1995 diagnosed cases; the study also did not
include all SEER areas. Among 86,298 men with stage I
and II prostate cancers reported to the National Cancer
Data Base (NCDB) with 1998 diagnoses, 39% were
treated with surgery, 42% received radiation, 18% were
managed conservatively (watchful waiting with or with-
out hormone therapy), and 1% received other specified
therapy. Of the patients treated surgically, 78% received a
radical prostatectomy, or 31% overall [13]. Whereas we
observed a higher radical prostatectomy rate than seen in
NCDB, our radiation therapy rate was considerably lower.
In addition to changing temporal trends, this may also
reflect differences between population-based data and
data based on selected hospitals (i.e., American College of
Surgeons (ACoS) approved hospitals), albeit covering all
states. Patients treated at ACoS approved hospitals may
have better insurance and better socioeconomic status in
general [14].
Geographic difference in treatment patterns persisted
by state after adjustment for other factors, both in terms
of definitive treatment versus conservative treatment and
radiation therapy versus radical prostatectomy. New York
was the only state in which radiation therapy was the
most common treatment modality. State differences have
been reported in a number of studies [11,15,16], includ-
ing generally higher prostatectomy rates in the Moun-
tain-Pacific region than in the Northeast and the
converse for radiation therapy [17,18]. Interstate differ-
ences in treatment patterns probably reflect local practice
patterns [19] as well as access to treatment facilities.
Our observation that black patients were more likely to
be treated conservatively than white patients is generally
consistent with previous studies [11,14,16,17,20-23] and
has been related to the lower likelihood of black men to
undergo radical prostatectomy [11,16,17,20,22-25]. We
found that among men receiving definitive therapy, treat-
ment selection did not differ by race except in patients
under age 60. In this age group black men were much
more likely to receive radiation therapy than radical pros-
tatectomy. Race-related differences in prostate cancer
treatment patterns remain poorly understood. If social
and economic disparities were the underlying factors
determining the racial variation, then one would also
expect lower utilization of radiation therapy and hor-
mone treatment, which has not been consistently
observed.
Consistent with treatment guidelines [26], we found
that clinical factors such as life expectancy, PSA level,
Gleason score, and competing medical conditions affect
prostate cancer treatment selection. We found that
unmarried men were more likely to receive conservative
treatment, which was also observed by Harlan et al
(2001). However, in their study, marital status was not
associated with treatment selection among men receiving
definitive treatment, whereas, in ours, unmarried men
were more likely to receive radiation therapy. We also
found that men with public health insurance were more
likely to receive conservative treatment, which was not
observed by Harlan et al (2001). Among men receiving
definitive treatment, no association was observed with
type of insurance. After multivariable adjustment, we
found no association between treatment and area-based
socioeconomic measures.
Survival of patients in this study was related to age,
marital status, Gleason score, comorbid illness, type of
treatment, and state of residence; unlike in some other
studies, survival did not differ by race [27-29]. Although
patients in this study were diagnosed with clinically local-
ized disease, 9% had a Gleason score of 8 to 10, which is
very predictive of nodal involvement [30] and, thus, lower
survival. The observed attenuation in the effect of comor-
bidity on all-cause mortality with time may reflect under-
ascertainment of comorbidities in our study since a
strong association with comorbidity score and ten-year
all-cause mortality has been previously reported [31].
To date, only three completed randomized trials have
compared effectiveness between major prostate cancer
treatment categories; none of these enrolled men with
primarily PSA-detected cancer, which limits their appli-
cability to current practice [32]. Two trials compared rad-
ical prostatectomy with watchful waiting. In the Veterans
Administration Cooperative Urological Research Group
(VACURG) study [33], the median overall survival was
10.6 years for the radical prostatectomy group and 8 years
for the watchful waiting group after a median follow-up
of 23 years. Results were not statistically significant, but
this study had limited power since it only included 142
patients. The Scandinavian trial, which included 695
men, did not find a statistically significant difference in
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Page 8 of 15overall survival at 5 or 8 years of follow-up [34]; but after
10 years found a 5% absolute risk reduction (0.74 relative
risk, p = 0.04) in overall mortality in the radical prostatec-
tomy group [35]. At 12 years, the all-cause mortality rela-
tive risk was attenuated and no longer statistically
significant [36]. In the same trial, radical prostatectomy
reduced prostate cancer-specific mortality as well as risk
of distant metastases; these benefits were evident at 5
years of follow-up and showed little or no further
increase in benefit 10 or more years after surgery [34-36].
The third trial, which compared radical prostatectomy
with external beam radiation therapy, did not evaluate
survival but found that surgery was more effective in pre-
venting progression, recurrence, or distant metastases in
patients with non-PSA detected cancers [32].
In our study five-year overall survival for radical pros-
tatectomy was significantly higher than for the other
three treatment modalities. However, when subdividing
radiation therapy, we found that survival following
brachytherapy was comparable. Although there appeared
to be a slight survival advantage for radiation therapy
compared to conservative management, even when lim-
Table 2: Distribution of initial treatment by clinical and tumor characteristics.
Percent receiving each therapy











Yes 2,106 (63) 2,092 (63) 43.45 34.46 9.70 12.38 <0.0001
No 864 (26) 855 (26) 31.70 25.73 10.76 31.81
Unknown 358 (11) 353 (11) 36.83 27.20 12.46 23.51
DRE results
Normal 1,312 (39) 1,301 (39) 42.51 28.67 9.76 19.06 <0.0001
Abnormal 1,086 (33) 1,081 (33) 37.47 38.48 11.84 12.21
Equivocal/
unk
930 (28) 918 (28) 38.34 27.02 9.15 25.49
PSA value
0-4 290 (9) 289 (9) 43.94 28.72 5.19 22.15 <0.0001
>4-10 1,603 (48) 1,599 (48) 46.78 33.27 7.57 12.38
>10-20 617 (19) 608 (18) 33.22 38.82 12.01 15.95
>20-50 260 (8) 254 (8) 20.87 35.04 22.83 21.26
50+ 111 (3) 111 (3) 20.72 27.03 24.32 27.93
Unknown 447 (13) 439 (13) 35.76 15.26 10.25 38.72
Gleason score
2-4 352 (11) 347 (11) 31.70 23.92 7.49 36.89 <0.0001
5-7 2,475 (74) 2,459 (75) 44.57 30.87 8.95 15.62
8-10 289 (9) 285 (9) 25.96 40.70 21.40 11.93
Unknown 212 (6) 209 (6) 14.35 37.80 15.31 32.54
Comorbidity 
score
0 2,772 (83) 2,749 (83) 41.36 32.34 9.28 17.02 <0.0001
1 441 (13) 437 (13) 33.87 27.69 11.90 26.54
2+ 115 (3) 114 (3) 21.93 23.68 28.07 26.32
1: Sample size for analysis of conservative versus definite therapy.
2: Sample size for dividing conservative treatment into hormone therapy and watchful waiting (excludes 28 observations missing dates for 
hormone therapy). Used for calculating proportions in this table.
3: Probability from a two-sided X2 test comparing the distribution of treatments across levels of the variable.
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Page 9 of 15Table 3: Percentage (%) distributions and odds ratios for receipt of conservative therapy (n = 3,328).
Characteristic % Crude 1 OR (95% CI) Adj.2 OR (95% CI)
Age at diagnosis
<60 12.13 1.00 (referent) 1.00 (referent)
60-64 17.96 1.59 (1.15 - 2.20) 1.65 (1.18 - 2.33)
65-69 20.38 1.85 (1.37 - 2.52) 1.90 (1.38 - 2.63)
70-74 32.58 3.50 (2.63 - 4.71) 3.35 (2.46 - 4.59)
75-79 46.71 6.35 (4.70 - 8.67) 6.76 (4.87 - 9.47)




27.59 1.00 (referent) 1.00 (referent)
Non-Hispanic 
Black
37.85 1.60 (1.30 - 1.96) 1.65 (1.28 - 2.13)
Non-Hispanic 
Other
33.93 1.35 (0.76 - 2.33) 1.28 (0.66 - 2.40)
Hispanic 35.96 1.47 (0.99 - 2.17) 1.56 (0.98 - 2.45)
Unknown 36.36 1.50 (0.60 - 3.52) 1.02 (0.31 - 3.02)
Marital status
Married 25.16 1.00 (referent) 1.00 (referent)
Not Married 42.81 2.23 (1.86 - 2.67) 1.72 (1.39 - 2.14)
Unknown 42.22 2.17 (1.59 - 2.96) 1.70 (1.15 - 2.49)
Insurance
Private/other 26.03 1.00 (referent) 1.00 (referent)
None 30.77 1.26 (0.52 - 2.83) 2.31 (0.89 - 5.52)
Public 40.18 1.91 (1.58 - 2.31) 1.51 (1.20 - 1.89)
Unknown 38.98 1.82 (1.39 - 2.37) 1.60 (1.14 - 2.25)
Registry
California 31.56 1.00 (referent) 1.00 (referent)
Colorado 27.50 0.82 (0.63 - 1.08) 1.37 (0.99 - 1.90)
Illinois 32.38 1.04 (0.80 - 1.35) 0.95 (0.68 - 1.32)
Louisiana 31.13 0.98 (0.75 - 1.28) 0.59 (0.42 - 0.82)
New York 26.07 0.77 (0.58 - 1.01) 0.85 (0.60 - 1.20)
Rhode Island 29.31 0.90 (0.68 - 1.18) 1.12 (0.80 - 1.56)
South 
Carolina
27.07 0.81 (0.60 - 1.09) 0.63 (0.43 - 0.91)
Screen-detected
Yes 22.60 1.00 (referent) 1.00 (referent)
No 43.17 2.60 (2.20 - 3.08) 2.32 (1.86 - 2.91)
Unknown 36.87 2.00 (1.57 - 2.53) 1.47 (1.08 - 1.99)
DRE results
Normal 29.42 1.00 (referent) 1.00 (referent)
Abnormal 24.40 0.77 (0.65 - 0.93) 0.67 (0.54 - 0.84)
Equivocal/
unknown
35.48 1.32 (1.10 - 1.58) 0.91 (0.73 - 1.15)
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Page 10 of 15ited to external beam radiation, and for watchful waiting
compared to hormone therapy, these differences were not
statistically significant after adjusting for other factors.
Our findings are generally consistent with those from
other observational studies, which have shown an overall
survival advantage for definitive treatment versus watch-
ful waiting [37] and no overall survival advantage for hor-
mone therapy compared to watchful waiting [38]. A
recent trial of immediate versus deferred androgen depri-
vation, which our study did not examine, found a modest
increase in overall survival for immediate androgen
deprivation [39]. In observational studies such as ours,
caution must be exercised in attributing survival differ-
ences to treatment received since healthier patients are
more likely to be treated aggressively and residual con-
founding cannot be discounted [40,41].
Our study was subject to several limitations. Because of
our reliance on medical records, we were not able to dis-
tinguish between actual watchful waiting and surveil-
lance, the latter being an active management process
where "curative" treatment may be applied if progression
is noted. This may explain why we observed somewhat
better survival for watchful waiting than for hormone
therapy.
Significant advances have been made in the treatment
of prostate cancer since 1997. Radical prostatectomy is
increasingly being performed laparoscopically. Three
dimensional conformal radiotherapy (3D-CRT), which
had been the accepted standard of external beam therapy
until the past 5-7 years, is being supplanted by intensity
modulated radiation therapy and stereotactic body radio-
therapy, and to a lesser extent, proton beam radiotherapy.
However, although practice patterns may have changed,
understanding the factors associated with choice of defi-
nite treatment versus conservative management remains
relevant.
Another limitation is lack of information on patient
preferences, their attitudes toward the medical system as
well as on the patient and physician decision-making pro-
cess. Prostate cancer treatment selection is influenced by
external recommendations, concerns about effects of
treatment on quality of life, characteristics of the treat-
ment itself, economic and logistic considerations, as well
as by personal perceptions and values [42,43]. In one
study prostate cancer patients reported that the physician
was the most important factor influencing their treat-
ment decision [44]. Other studies found that treatment
selection for prostate cancer was related to the treatment
options that were discussed [11], the information patients
received [45], and the extent to which patients were
involved in the decision-making process [46]. Patient
involvement in the choice of treatment is particularly
important in early stage prostate cancer because the vari-
ous treatment regimens often involve significant side
effects [47-49] that impact quality of life and patient satis-
faction with treatment outcomes [50-52].
Although this study included samples from seven states
and resulted in a fairly large sample size, results may not
be generalizable to the entire country. Additionally, the
study did not over-sample minorities. Therefore, the
PSA value
0-4 27.59 1.00 (referent) 1.00 (referent)
>4-10 20.15 0.66 (0.50 - 0.88) 0.69 (0.50 - 0.97)
>10-20 29.01 1.07 (0.79 - 1.47) 0.80 (0.56 - 1.15)
>20-50 45.38 2.18 (1.53 - 3.12) 1.41 (0.93 - 2.15)
50+ 52.25 2.87 (1.83 - 4.53) 1.73 (1.02 - 2.94)
Unknown 49.89 2.61 (1.91 - 3.60) 1.64 (1.12 - 2.41)
Gleason score
2-4 45.17 1.00 (referent) 1.00 (referent)
5-7 25.05 0.41 (0.32 - 0.51) 0.45 (0.34 - 0.59)
8-10 34.26 0.63 (0.46 - 0.87) 0.49 (0.33 - 0.72)
Unknown 48.58 1.15 (0.88 - 1.61) 0.75 (0.50 - 1.13)
Comorbidity 
score
0 26.91 1.00 (referent) 1.00 (referent)
1 39.00 1.74 (1.41 - 2.14) 1.44 (1.12 - 1.86)
2+ 54.78 3.29 (2.26 - 4.81) 2.59 (1.67 - 4.03)
1: OR = odds ratio; CI = confidence interval.
2: Adjusted for factors shown in the table.
Table 3: Percentage (%) distributions and odds ratios for receipt of conservative therapy (n = 3,328). (Continued)
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Table 4: Percentage (%) distributions and odds ratios for receipt of radiation therapy among patients receiving definitive 
treatment (n = 2,347).
Characteristic % Crude 1 OR (95% CI) Adj.2 OR (95% CI) Adj.3 OR (95% CI)
Model 1 Model 2
Age-Race/ethnicity
Interaction4
<60, Non-Black 1.00 (referent) 1.00 (referent)
<60, NH Black 2.98 (1.77 - 4.96) 2.62 (1.50 - 4.52)
60-64, Non-Black 2.01 (1.42 - 2.88) 1.95 (1.36 - 2.83)
60-64, NH Black 2.80 (1.52 - 5.03) 2.53 (1.32 - 4.72)
65-74, Non-Black 7.20 (5.38 - 9.79) 7.55 (5.57 - 10.40)
65-74, NH Black 5.14 (3.24 - 8.18) 5.19 (3.15 - 8.59)
>= 75, Non-Black 68.08 (41.57 - 116.45) 69.73 (41.94 - 120.93)
>= 75, NH Black 41.09 (13.58 - 178.13) 43.31 (13.28 - 196.39)
Age at diagnosis
<60 17.20 1.00 (referent) 1.00 (referent)
60-64 25.54 1.65 (1.22 - 2.25) 1.63 (1.18 - 2.26)
65-69 39.76 3.18 (2.41 - 4.22) 3.37 (2.52 - 4.54)
70-74 69.25 10.84 (8.08 - 14.66) 12.22 (8.94 - 16.86)
>= 75 91.32 50.63 (32.27 - 82.56) 54.47 (34.11 - 90.27)
Marital status
Married 42.30 1.00 (referent) 1.00 (referent) 1.00 (referent)
Not Married 49.18 1.32 (1.05 - 1.65) 1.44 (1.10 - 1.88) 1.51 (1.15 - 1.98)
Unknown 60.58 2.10 (1.41 - 3.16) 2.20 (1.36 - 3.58) 2.22 (1.36 - 3.65)
Registry
California 36.60 1.00 (referent) 1.00 (referent) 1.00 (referent)
Colorado 39.30 1.12 (0.83 - 1.52) 1.57 (1.10 - 2.25) 1.60 (1.11 - 2.31)
Illinois 46.46 1.50 (1.11 - 2.04) 1.57 (1.09 - 2.27) 1.71 (1.17 - 2.49)
Louisiana 38.36 1.08 (0.80 - 1.46) 1.06 (0.73 - 1.53) 1.07 (0.74 - 1.56)
New York 53.80 2.02 (1.49 - 2.75) 2.40 (1.66 - 3.49) 2.78 (1.91 - 4.06)
Rhode Island 49.39 1.69 (1.24 - 2.30) 2.00 (1.39 - 2.90) 1.98 (1.36 - 2.89)
South Carolina 47.66 1.58 (1.14 - 2.19) 2.12 (1.43 - 3.14) 2.35 (1.58 - 3.51)
DRE results
Normal 40.28 1.00 (referent) 1.00 (referent) 1.00 (referent)
Abnormal 50.67 1.52 (1.26 - 1.84) 1.19 (0.95 - 1.50) 1.17 (0.93 - 1.48)
Equivocal/unknown 41.33 1.05 (0.85 - 1.29) 0.78 (0.60 - 1.02) 0.77 (0.59 - 1.00)
PSA value
0-4 39.52 1.00 (referent) 1.00 (referent) 1.00 (referent)
>4-10 41.56 1.09 (0.81 - 1.47) 1.01 (0.71 - 1.44) 1.06 (0.74 - 1.53)
>10-20 53.88 1.79 (1.28 - 2.50) 1.57 (1.06 - 2.34) 1.64 (1.09 - 2.46)
20+ 61.00 2.40 (1.61 - 3.58) 2.14 (1.34 - 3.45) 2.17 (1.35 - 3.52)
Unknown 29.91 0.65 (0.44 - 0.97) 0.45 (0.27 - 0.73) 0.46 (0.28 - 0.75)
Gleason score
2-4 43.01 1.00 (referent) 1.00 (referent) 1.00 (referent)
5-7 40.92 0.92 (0.68 - 1.24) 0.76 (0.54 - 1.09) 0.76 (0.53 - 1.09)
8-10 61.05 2.08 (1.39 - 3.13) 1.53 (0.94 - 2.48) 1.59 (0.97 - 2.62)
Unknown 72.48 3.49 (2.12 - 5.86) 5.59 (3.09 - 10.34) 5.64 (3.08 - 10.52)
1: OR = odds ratio; CI = confidence interval.
2,3: Adjusted for factors shown in the table.
4: NH = Non-Hispanic, non-Black includes all race/ethnic groups other than NH Blacks.
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Page 12 of 15number of non-white and Hispanic prostate cancer
patients was still relatively small and may not have
allowed us to adequately assess racial and ethnic differ-
ences. Furthermore, the five-year lag between cancer
diagnosis and data collection resulted in difficulty
retrieving some medical information. Reliance on face
sheets in medical records for comorbidity information
probably led to under-ascertainment of comorbidities.
The study also did not have access to individual-level
measures of socioeconomic status and relied instead on
area-derived Census measures. This may have resulted in
inadequate adjustment for socioeconomic effects. Finally,
we were unable to examine cause-specific mortality in
addition to overall mortality.
The CDC-NPCR Patterns of Care study follows the
Institute of Medicine recommendations that data systems
such as SEER and NPCR be used to conduct surveillance
of treatment in the United States [7]. Although a number
of prostate cancer patterns of care studies have been con-
ducted using data from the SEER program, this is the first
such study using data from the NPCR. There is some evi-
dence to suggest that patients residing in SEER areas are
somewhat more affluent [53] and may have greater access
to high quality cancer care. Of the seven states that par-
ticipated in this study, none was part of the SEER pro-
gram in 1997, and several had not participated in
previous patterns of care studies (e.g., New York). For
these states, this study was very significant in that it pro-
vided them with valuable baseline treatment information
and enhanced their capacity to conduct treatment sur-
veillance. The present study also serves as the foundation
for future NPCR patterns of care studies, one of which is
currently in progress [54]. The second NPCR Patterns of
Care study addresses several limitations of the current
study. In particular, sampling was stratified by race, and
more detailed treatment data are being collected, includ-
ing radiation dose.
Conclusions
The fact that geographic variation remained even after
adjusting for other factors, both in treatment patterns as
well as in survival, suggests true regional differences in
how physicians and patients select treatment options.
Factors affecting treatment choice and treatment effec-
tiveness need to be further explored in future population-
based studies. Prostate cancer treatment contributes sig-
nificantly to national healthcare costs because of the
sheer number of men who are affected [55], with the cost
per patient dependent on the type of treatment received
[56]. Given the current healthcare reform discussions, a
thorough understanding of the factors driving treatment
selection is both critical and timely [57].
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Table 5: Alternate presentations of odds ratios by age and race for receipt of radiation therapy among patients receiving 
definitive treatment (model 1 from Table 4).
Non-Black Non-Hispanic Black
Age OR (95% CI) OR (95% CI)
OR(Age) within Strata of Race
<60 1.00 referent 1.00 referent
60-64 1.95 (1.36 - 2.83) 0.97 (0.46 - 2.00)
65-74 7.55 (5.57 - 10.40) 1.98 (1.08 - 3.70)
75+ 69.73 (41.94 - 120.93) 16.53 (4.80 - 77.66)
OR(Race) within Strata of Age
Age
<60 1.00 referent 2.62 (1.50 - 4.52)
60-64 1.00 referent 1.30 (0.69 - 2.37)
65-74 1.00 referent 0.69 (0.44 - 1.06)
75+ 1.00 referent 0.62 (0.18 - 2.90)
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Page 13 of 15Table 6: Five-year survival and crude and adjusted hazard ratios by sociodemograhic and clinical factors (n = 3,297).
Characteristic 5 yr Survival1(%) Crude Hazard Ratio (95% CI)2 Adjusted3 Hazard Ratio (95% CI)
Age at diagnosis
<60 95.06 1.00 (referent) 1.00 (referent)
60-64 93.38 1.38 (0.86 - 2.20) 1.28 (0.80 - 2.04)
65-69 87.92 2.59 (1.73 - 3.89) 2.10 (1.39 - 3.18)
70-74 85.60 3.33 (2.24 - 4.95) 2.28 (1.51 - 3.46)
75-79 74.67 6.18 (4.18 - 9.14) 3.67 (2.41 - 5.60)
>= 80 50.82 13.00 (8.78 - 19.25) 5.29 (3.43 - 8.16)
Race/ethnicity
Non-Hispanic White 85.42 1.00 (referent) 1.00 (referent)
Non-Hispanic Black 78.78 1.47 (1.18 - 1.83) 1.17 (0.92 - 1.48)
Non-Hispanic Other 94.51 0.31 (0.10 - 0.95) 0.35 (0.11 - 1.10)
Hispanic 92.65 0.51 (0.27 - 0.96) 0.53 (0.28 - 1.00)
Unknown 78.25 1.40 (0.52 - 3.74) 1.29 (0.46 - 3.61)
Marital status
Married 86.36 1.00 (referent) 1.00 (referent)
Not Married 78.58 1.69 (1.40 - 2.05) 1.21 (1.00 - 1.48)
Unknown 86.39 0.90 (0.59 - 1.35) 0.67 (0.43 - 1.03)
Registry
California 86.03 1.00 (referent) 1.00 (referent)
Colorado 89.97 0.79 (0.56 - 1.10) 0.94 (0.66 - 1.33)
Illinois 82.36 1.35 (1.00 - 1.82) 1.01 (0.74 - 1.38)
Louisiana 78.80 1.69 (1.28 - 2.25) 1.37 (1.02 - 1.84)
New York 86.90 1.01 (0.73 - 1.40) 1.10 (0.78 - 1.54)
Rhode Island 88.38 0.91 (0.65 - 1.27) 0.82 (0.58 - 1.16)
South Carolina 79.79 1.72 (1.21 - 2.44) 1.54 (1.06 - 2.24)
PSA value
0-4 90.49 1.00 (referent) 1.00 (referent)
>4-10 89.28 1.00 (0.69 - 1.44) 1.07 (0.73 - 1.55)
>10-20 84.65 1.50 (1.01 - 2.21) 1.20 (0.81 - 1.79)
20+ 75.77 2.43 (1.64 - 3.60) 1.38 (0.92 - 2.09)
Unknown 73.16 2.65 (1.80 - 3.90) 1.82 (1.22 - 2.70)
Gleason score
2-4 83.90 1.00 (referent) 1.00 (referent)
5-7 86.73 1.10 (0.81 - 1.50) 1.35 (0.98 - 1.85)
8-10 73.69 2.21 (1.54 - 3.19) 1.96 (1.34 - 2.86)




93.68 1.00 (referent) 1.00 (referent)
Radiation therapy 85.99 2.55 (1.97 - 3.31) 1.66 (1.24 - 2.21)
Hormonal therapy 65.24 6.75 (5.13 - 8.88) 2.83 (2.06 - 3.90)
Watchful waiting 75.47 4.73 (3.65 - 6.14) 2.30 (1.70 - 3.12)
Comorbidity score4
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